Safety and Efficacy of Baricitinib through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161
Arthritis Res Ther. 2017 Jul 4;19(1):155. doi: 10.1186/s13075-017-1346-5
Clin Exp Rheumatol 2017;35:689–99
Arthritis Care Res (Hoboken). 2017 Oct;69(10):1484-1494. doi: 10.1002/acr.23303
Lancet 2017;389:2328–37 DOI 10.1016/S0140-6736(17)31472-1
Arthritis Rheumatol. 2017 Oct;69(10):1949-1959. doi: 10.1002/art.40186
Cochrane Database Syst Rev. 2017 May 8;5:CD012657. doi: 10.1002/14651858.CD012657
Ann Rheum Dis 2017;76:1009–19
Ann Rheum Dis 2017;76:998–100
J Med Econ 2017;20:464–73